ONELIFE Senior Living Assumes Management of The Vineyard at Fountaingrove in Santa Rosa, California
The community will soon be rebranded as The Reserve at Fountaingrove Memory Care, symbolizing a fresh start and renewed commitment to exceptional care for residents living with Alzheimer's and other memory-related conditions.
This latest acquisition brings Onelife's portfolio to 15 communities, including five in California. Following an early 2024 merger with Ally Senior Living, Onelife has more than doubled its number of properties in just six months. This expansion aligns with the organization's mission to meet the growing demand for specialized memory care services across the state.
'The Vineyard at Fountaingrove Memory Care will be our fifth community in California,' said Dan Williams, CEO of ONELIFE Senior Living. 'We are committed to expanding in California, where approximately 720,000 individuals aged 65 and older were living with Alzheimer's disease in 2023. With this number expected to reach nearly 1.2 million by 2030, Onelife is focused on meeting the growing need for specialized memory care.'
Living and Care Options
The Vineyard at Fountaingrove Memory Care is a premier residential community dedicated to supporting individuals with Alzheimer's, dementia, and other memory-related conditions. Residents benefit from a secure and nurturing environment where personalized care, thoughtfully designed spaces, and enriching daily activities foster comfort, dignity, and a true sense of belonging.
The Vineyard offers a variety of floor plans, including private and neighbor suites, allowing families to select the option that best suits their loved one's preferences and budget. With no buy-in fees or long-term lease commitments, The Vineyard at Fountaingrove provides families with the flexibility and peace of mind they deserve. Nestled in the scenic Fountaingrove neighborhood of Santa Rosa, the community combines comfort and care to create a welcoming home for all residents.
Resident Safety and Staff
The Vineyard prioritizes resident safety and independence, with caregivers available 24/7 and a licensed nurse overseeing care daily. Call systems provide added security, while weekly housekeeping and personal laundry services enhance convenience for residents.
Activities and Amenities
The Vineyard offers a vibrant lifestyle with personalized activities that promote joy and connection. Residents enjoy music and art therapy, fitness classes, interactive games, and social gatherings designed to support cognitive and physical well-being. Thoughtfully designed amenities include built-in storage, hardwood-style flooring, garden views, and home-cooked meals served in spacious neighborhood kitchens. With 24-hour staff availability and an on-site salon and barbershop, The Vineyard ensures comfort and care every day.
To contact Onelife or schedule a tour at The Vineyard at Fountaingrove Memory Care, visit www.reservefountaingrove.com.
Founded in 2009, Denver-based Onelife Senior Living is a family-owned developer and operator of a growing collection of independent, assisted living and memory care communities designed to provide seniors with the care, support and encouragement they need to live healthy, happy lives.
Contact Information:
ONELIFE Senior Living
206-499-9898
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
10 hours ago
- Newsweek
A Doctor's Plea From a Nation Asleep on Brain Disease
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As a physician who once treated pain, I now endure the unimaginable. Amyotrophic lateral sclerosis (ALS) has left me quadriplegic, dependent on a tracheostomy to breathe and a feeding tube to eat. Diagnosed at 35, my career ended abruptly. My family's story reveals the scale of the coming storm—my father battles Alzheimer's, my uncle succumbed to Parkinson's, and my grandmother to Lewy body dementia. We are not outliers; we represent a silent epidemic. Neurodegenerative diseases are surging, yet our nation slumbers, unaware of the devastation ahead. The public's complacency is by design, built on a statistical illusion. ALS, fatal since 1869, exemplifies this peril. With a median survival of 2-3 years, it strikes about 1 in 300 people in their lifetime, which predicts that over 1 million people now alive in the U.S. will succumb to ALS. Yet, under federal law, it is labeled "rare" because that definition is based on prevalence—a static snapshot of how many people are living with a disease at one time. Because ALS kills its victims so quickly, the number of living patients stays below the 200,000-person "rare" threshold. Its very lethality ensures it is never treated like the mainstream public health crisis it is. This paradox obscures a terrifying forecast: a projected 69 percent global increase in ALS cases by 2040. This illusion of rarity perpetuates a deadly inaction that extends to all brain diseases. Alzheimer's already affects over 7 million Americans and is projected to strike nearly 13 million by 2050, costing our economy $384 billion in 2025—and projected to nearly $1 trillion annually by mid-century. Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Getty Images The failure to confront this crisis stems from a Tale of Two Agencies within the Food and Drug Administration (FDA). In 2017, Congress established the Oncology Center of Excellence (OCE), a dynamic hub that has revolutionized cancer treatment, accounting for 85 percent of all accelerated approvals in the last decade. This success is the result of focused will and resources; National Institutes of Health (NIH) funding for cancer has topped $7.2 billion, compared to $2.8 billion for neuroscience. Neurology has no such center. Lacking an institutional home, it is fragmented, slow, and characterized by a risk aversion unthinkable in oncology. This disparity persists because of the tragic nature of these diseases. In the 1980s, ACT UP activists staged "die-ins" to force a reluctant government to fight AIDS. Patients with ALS, Huntington's, or Alzheimer's cannot mount a similar protest—we are physically silenced and immobilized, unable to "seize the FDA." This vulnerability places a unique moral obligation on our leaders to act proactively on behalf of the voiceless. The new FDA leadership now arrives with bold promises of change, posing a question that haunts everyone touched by an untreatable neurological disease: Will this time be different? Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. vows to "sweep away barriers" and to "figure out new ways ... of accelerating approvals for drugs and treatments that treat rare diseases." FDA Commissioner Marty Makary has several times asked why it takes 10 years for a drug to get to market and proposes a "conditional approval" pathway based on a "plausible mechanism." Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad promised to "take action at the first sign of promise for rare diseases." For the ALS community, these words are now a crisis of credibility. In a disease that has a median survival of 2-3 years, we are asking for regulatory flexibility for a treatment that began its Phase 1 trial in 2011 and was granted FDA Fast Track designation in 2014. As a petitioner on the July 3 citizens' petition for a stem cell therapy known as NurOwn, my community has presented the FDA with a clear test. Ultimately, we are seeking accelerated approval based on new, unprecedented survival data from an expanded access program—data that exceeds the extension of survival of many approved cancer therapies. But the initial request is simpler: invite the sponsor to resubmit its application for a full review. Ours is a request for due process to give a voice to the voiceless—the lowest possible bar for the Trump administration to demonstrate its promised flexibility. A clear, bipartisan solution has already failed once. The Neuroscience Center of Excellence Act, introduced in 2021 to replicate oncology's success for brain disease, stalled in committee. It is time for our leaders to find the political will that has been so catastrophically absent. Congress must immediately revive and pass the Neuroscience Center of Excellence Act. The FDA, in turn, must match its leaders' promises with action by granting our petition a review. The science is poised for breakthroughs, but it is being shackled by a broken system. For those of us on a deadline, this is not a policy debate. It is a death sentence. Awaken now, before this silent storm engulfs us all. The voiceless can't wait. Dr. Shahriar Minokadeh, a former anesthesiologist trained at Johns Hopkins and pain management at UC San Diego, types via an eye-gaze device. The views expressed in this article are the writer's own.
Axios
11 hours ago
- Axios
After 60,000 miles running, this 75-year-old is ready for an ultramarathon
For more than four decades now, Tom Carr, a retired school counselor living in Hillsborough, has been recording the results of his near-daily runs. Turns out you can get pretty far by the time you're 75. Why it matters: Carr is a testament to the power of consistency and the longevity that can come from showing up every day without fail. Carr has now run more than 60,000 miles in his lifetime, all of them outside in the elements and all of them, he says, are vital to keeping his head on straight. Driving the news: Later this month, Carr will attempt his longest run yet — a 100-mile ultramarathon that most people wouldn't dream of completing, let alone in their eighth decade. The race, called A Race for the Ages in Tennessee, will give him exactly 75 hours to finish the 100 miles. It starts Aug. 28. Zoom in: Carr is one of the founding members of the Hillsborough Running Club, embracing the sport before it was a mainstream pursuit and helping organize races in Orange County. He chalks up his longevity to the power of consistency and to what he believes are the therapeutic effects of breathing in fresh air and listening to the soundscapes of the woods. He also never embarks on a run without eating a peanut butter and jelly bagel. (The jelly has to be sugar-free Smuckers; the peanut butter could be anything.) No matter what, he never listens to music or a podcast, which he believes can stop the flow of creative thoughts when running alone. For years, he carried a notebook to jot down all the thoughts that would race through his mind on the run. Without that, he says, he would never have been able to write 15 books on education issues. Yes, but: Running has also helped manage some of the hardest moments of Carr's life, including losing Carlye, his partner of 53 years, last year to the effects of Alzheimer's. Carr's hoping to use the 100-mile race to raise money for the Alzheimer's Association in her honor. "If I wasn't able to get out of the house and go running, I don't know how I would have survived that difficult period of time," Carr said of his wife's health. "I think about her a whole lot when I'm when I'm out on the run, and I'm still struggling with it", he added. "With Alzheimer's, you know, her reasoning and her thinking, it wasn't there, so we didn't have any closure." Now, in a period where research funding is being cut, Carr believes the "Alzheimer's Association needs all the help they can get." What they're saying: One unexpected benefit of never giving up the daily habit of running, according to Carr, is that he is finally winning awards at races he competes in. While he never had blazing speed in his most athletic years — he describes himself as slow and steady — Carr now routinely finishes at the top of his age group when he runs a marathon or 5k. "There's not a lot of people in the 75 and up age group," he said, laughing. "I didn't win any medals or trophies or nothing until I was in my 60s!"
The Hill
21 hours ago
- The Hill
Senate panel rejects Trump budget health cuts
The White House budget called for slashing NIH by $18 billion, a decrease of 40 percent. Instead, the committee advanced the bill on a 26-3 vote, delivering a bipartisan rebuke of the administration's efforts to defund medical research. The bill includes a $100 million increase for Alzheimer's disease research, a $150 million increase for cancer research and a $30 million increase for the Office of Research on Women's Health. While funding for other parts of the Department of Health and Human Services (HHS) was left the same, it was still a far cry from the major cuts put forward by the White House. 'To the scientists wondering if there will even be an NIH by the end of this administration: this committee's resounding message is yes,' said Sen. Patty Murray (D-Wash.), the committee's vice chair. The panel also did not include a massive HHS reorganization that would have created a new Administration for a Healthy America (AHA) to focus on chronic disease prevention. The White House budget request called for the new AHA agency to absorb other existing agencies and programs within the Centers for Disease Control and Prevention, as well as the entire Substance Abuse and Mental Health Services Administration, the Health Resources and Services Administration, the Office of the Assistant Secretary for Health, and the National Institute of Environmental Health Sciences. The administration proposed giving the AHA agency a budget of $20 billion. But lawmakers on Thursday never mentioned it. An Appropriations Committee spokesperson told The Hill that HHS never sent Congress the required formal reorganization plan or allow for six months of consideration.
